- Cyclooxygenase 2
- Genetic variation
- ω–3 fatty acids
- Polyunsaturated fatty acids
- Prostatic neoplasms
- Single nucleotide polymorphism
Dietary intake of fish and ω–3 polyunsaturated fatty acids (ω–3 PUFAs) may decrease the risk of prostate cancer development and progression to advanced stage disease. This could reflect the anti-inflammatory effects of PUFAs, possibly through mediation of cyclooxygenase (COX), a key enzyme in fatty acid metabolism and inflammation. Despite promising experimental evidence, epidemiological studies have reported somewhat conflicting results regarding the effects of fish/PUFAs on prostate cancer development and progression. The literature suggests that fish, and particularly long-chain ω–3 PUFAs, may have a more pronounced protective effect on biologically aggressive tumors or on their progression, and less on early steps of carcinogenesis. Moreover, the impact of LC ω–3 PUFAs may be modified by variation of the COX-2 gene. Overall, results to date support the hypothesis that long-chain ω–3 PUFAs may impact prostate inflammation and carcinogenesis via the COX-2 enzymatic pathway.
Copyright © 2009 S. Karger AG, Basel
- Society AC: Cancer Facts and Figures. Atlanta, American Cancer Society, 2009.
- Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO: Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277:467–471.
- Cooperberg MR, Broering JM, Carroll PR: Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;101:878–887.
- Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S: Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 2001;96:363–371.
- Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435–448.
- Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860–867.
- De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–269.
- Chan JM, Gann PH, Giovannucci EL: Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152–8160.
- Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13:72–79.
- Taylor ML, Mainous AG 3rd, Wells BJ: Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005;37:506–512.
- Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNA SEL variant. PLoS Pathog 2006;2:e25.
- Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE: Intra-prostatic urinary reflux: An aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729–731.
- Persson BE, Sjoman M, Niklasson F, Ronquist G: Uridine, xanthine and urate concentrations in prostatic fluid and seminal plasma of patients with prostatitis. Eur Urol 1991;19:253–256.
- Rose DP: Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 1997;216:224–233.
- Terry PD, Rohan TE, Wolk A: Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 2003;77:532–543.
- McEntee MF, Whelan J: Dietary polyunsaturated fatty acids and colorectal neoplasia. Biomed Pharmacother 2002;56:380–387.
- Riediger ND, Othman RA, Suh M, Moghadasian MH: A systemic review of the roles of n–3 fatty acids in health and disease. J Am Diet Assoc 2009;109:668–679.
- Calviello G, Serini S, Piccioni E, Pessina G: Antineoplastic effects of n–3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 2009;61:287–301.
- Russo GL: Dietary n–6 and n–3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 2009;77:937–946.
- Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G: Risks and benefits of omega-3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006;332:752–760.
- Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73–78.
- Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820–825.
- Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti- inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169–170.
- Norrish AE, Jackson RT, McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511–515.
- Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219–225.
- Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D: Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001;58:283–288.
- Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K: Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia 2006;8:112–124.
- Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A: Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia 2009;11:692–699.
- Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D’Agostino R, Zhang H, Wu H, Kang JX, Chen YQ: Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866–1875.
- McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N, Lih FB, O’Rourke D, Whelan J: Dietary n–3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am J Pathol 2008;173:229–241.
- Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A: Dietary long-chain n–3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935–945.
- Narayanan NK, Narayanan BA, Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappab, and steroid hormone receptors. Int J Oncol 2005;26:785–792.
- Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E: A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:64–67.
- Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A: Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764–1766.
- Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA: Association of energy and fat intake with prostate carcinoma risk: results from the Netherlands cohort study. Cancer 1999;86:1019–1027.
- Laaksonen DE, Laukkanen JA, Niskanen L, Nyyssonen K, Rissanen TH, Voutilainen S, Pukkala E, Hakkarainen A, Salonen JT: Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: a population-based cohort study. Int J Cancer 2004;111:444–450.
- Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN: Fat and meat intake and prostate cancer risk: The multiethnic cohort study. Int J Cancer 2007;121:1339–1345.
- Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL: Dietary intake of n–3 and n–6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 2004;80:204–216.
- Amin M, Jeyaganth S, Fahmy N, Begin LR, Aronson S, Jacobson S, Tanguay S, Kassouf W, Aprikian A: Dietary habits and prostate cancer detection: a case-control study. Can Urol Assoc J 2008;2:510–515.
- Mina K, Fritschi L, Johnson KC: An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. Nutr Cancer 2008;60:222–226.
- Fernandez E, Chatenoud L, La Vecchia C, Negri E, Franceschi S: Fish consumption and cancer risk. Am J Clin Nutr 1999;70:85–90.
- Bidoli E, Talamini R, Bosetti C, Negri E, Maruzzi D, Montella M, Franceschi S, La Vecchia C: Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005;16:152–157.
- Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, Shahedi K, Xu J, Adami HO, Gronberg H, Balter KA: Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 2007;120:398–405.
- Allen NE, Sauvaget C, Roddam AW, Appleby P, Nagano J, Suzuki G, Key TJ, Koyama K: A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 2004;15:911–920.
- Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC: A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571–1579.
- Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC: Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. Int J Cancer 2007;121:1571–1578.
- Ghadirian P, Lacroix A, Maisonneuve P, Perret C, Drouin G, Perrault JP, Beland G, Rohan TE, Howe GR: Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada. Cancer Causes Control 1996;7:428–436.
- Rohan TE, Howe GR, Burch JD, Jain M: Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 1995;6:145–154.
- Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, Trichopoulou A: Diet and cancer of the prostate: a case-control study in Greece. Int J Cancer 1999;80:704–708.
- Ramon JM, Bou R, Romea S, Alkiza ME, Jacas M, Ribes J, Oromi J: Dietary fat intake and prostate cancer risk: a case-control study in Spain. Cancer Causes Control 2000;11:679–685.
- Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J: A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr 2008;88:1297–1303.
- Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, Johnsen NF, Tjonneland A, Linseisen J, Rohrmann S, Boeing H, Pischon T, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Krogh V, Bueno-de-Mesquita HB, Kiemeney LA, Chirlaque MD, Ardanaz E, Sanchez MJ, Larranaga N, Gonzalez CA, Quiros JR, Manjer J, Wirfalt E, Stattin P, Hallmans G, Khaw KT, Bingham S, Ferrari P, Slimani N, Jenab M, Riboli E: Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2008;87:1405–1413.
- Koralek DO, Peters U, Andriole G, Reding D, Kirsh V, Subar A, Schatzkin A, Hayes R, Leitzmann MF: A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States). Cancer Causes Control 2006;17:783–791.
- Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA: Animal products, calcium and protein and prostate cancer risk in the Netherlands cohort study. Br J Cancer 1999;80:1107–1113.
- Veierod MB, Laake P, Thelle DS: Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997;73:634–638.
- Wallstrom P, Bjartell A, Gullberg B, Olsson H, Wirfalt E: A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). Cancer Causes Control 2007;18:1107–1121.
- Andersson SO, Wolk A, Bergstrom R, Giovannucci E, Lindgren C, Baron J, Adami HO: Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 1996;68:716–722.
- Kristal AR, Cohen JH, Qu P, Stanford JL: Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:719–725.
- Kolonel LN: Fat, meat, and prostate cancer. Epidemiol Rev 2001;23:72–81.
- Pham TM, Fujino Y, Kubo T, Ide R, Tokui N, Mizoue T, Ogimoto I, Matsuda S, Yoshimura T: Fish intake and the risk of fatal prostate cancer: findings from a cohort study in Japan. Public Health Nutr 2009;12:609–613.
- Bairati I, Meyer F, Fradet Y, Moore L: Dietary fat and advanced prostate cancer. J Urol 1998;159:1271–1275.
- De Stéfani E, Deneo-Pellegrini H, Boffetta P, Ronco A, Mendilaharsu M: Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev 2000;9:335–338.
- Fradet V, Cheng I, Casey G, Witte JS: Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009;15:2559–2566.
- Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L: Dietary fat and prostate cancer survival. Cancer Causes Control 1999;10:245–251.
- Cancer Statistics in Japan, 2007.
- Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006;296:1885–1899.
- Brouwer A, Longnecker MP, Birnbaum LS, Cogliano J, Kostyniak P, Moore J, Schantz S, Winneke G: Characterization of potential endocrine-related health effects at low-dose levels of exposure to PCBS. Environ Health Perspect 1999;107(suppl 4):639–649.
- Ritchie JM, Vial SL, Fuortes LJ, Robertson LW, Guo H, Reedy VE, Smith EM: Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer. Environ Res 2005;98:104–113.
- Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H, Xu J: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006;119:668–672.
- Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS: COX2 genetic variation, NSAIDS, and advanced prostate cancer risk. Br J Cancer 2007;97:557–561.
- Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004;25:961–966.
- Massaro M, Habib A, Lubrano L, Del Turco S, Lazzerini G, Bourcier T, Weksler BB, De Caterina R: The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci USA 2006;103:15184–15189.
- Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145–182.
John S. Witte
Departments of Epidemiology and Biostatistics and Urology
Helen Diller Family Comprehensive Cancer Center, University of California
Diller Bldg, Room 388, 1450 3rd Street, MC 3110
San Francisco, CA 94158-9001 (USA), Tel. +1 415 502 6882, E-Mail firstname.lastname@example.org
Published online: September 23, 2009
Number of Print Pages : 10
Number of Figures : 1, Number of Tables : 2, Number of References : 73
Journal of Nutrigenetics and Nutrigenomics
Vol. 2, No. 3, Year 2009 (Cover Date: October 2009)
Journal Editor: Pérusse L. (Quebec, Que.)
ISSN: 1661-6499 (Print), eISSN: 1661-6758 (Online)
For additional information: http://www.karger.com/JNN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.